Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease…

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Trend
+0.2% vs SMA 50 · +14.4% vs SMA 200
Momentum
Strong accumulation on above-average volume. Buyers are absorbing supply aggressively — any positive catalyst could trigger a rapid covering move.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $190.7M $189.2M–$192.2M | — | $0.84 | — | ±1% | Low1 |
FY2024 | $194.9M $194.6M–$195.1M | ▲ +2.2% | $0.78 | ▼ -6.6% | ±1% | Low2 |
FY2025 | $241.0M $239.4M–$242.7M | ▲ +23.7% | $1.25 | ▲ +59.0% | ±1% | Moderate3 |
Dividend per payment — last 8 periods
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease…

Flushing Financial Corporation is the holding company for Flushing Bank®, a New York State—chartered commercial bank insured by the Federal Deposit Insurance Corporation.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
FFIC◀ | $16.14 | +0.12% | $547M | 15.9 | +1105.8% | 416.6% | 1500 |
| $312.47 | -0.24% | $842.7B | 14.8 | +330.7% | 2039.3% | 1502 | |
| $328.03 | -0.55% | $628.8B | 28.2 | +1134.0% | 5014.5% | 1498 | |
| $495.46 | -1.48% | $438.6B | 28.4 | +1641.6% | 4564.7% | 1488 | |
| $53.24 | -0.41% | $382.1B | 12.2 | -45.1% | 1592.6% | 1501 | |
| $190.18 | -0.22% | $302.0B | 16.4 | +1147.7% | 1466.4% | 1516 | |
| $923.71 | -0.01% | $274.1B | 15.5 | -138.4% | 1373.0% | 1515 | |
| Sector avg | — | -0.40% | — | 18.8 | +739.5% | 2352.4% | 1503 |